Financial Performance - Operating revenue for the first nine months of 2024 reached CNY 652,939,581.37, a 23.67% increase from CNY 527,964,172.48 in the same period of 2023[4] - Net profit attributable to shareholders rose by 36.43% to CNY 115,282,910.60, up from CNY 84,501,559.50 year-on-year[4] - Basic earnings per share rose to CNY 1.49, reflecting a 35.45% increase from CNY 1.10 in the previous year[4] - Total operating revenue for the first nine months of 2024 reached ¥652,939,581.37, a 23.6% increase from ¥527,964,172.48 in the same period of 2023[27] - Net profit for the first nine months of 2024 was ¥115,282,910.60, representing a 36.4% increase compared to ¥84,501,559.50 in the same period of 2023[28] - Total profit for the first nine months of 2024 was ¥136,903,204.15, an increase of 37.3% from ¥99,708,306.74 in the same period of 2023[28] - The company achieved a total comprehensive income of ¥115,282,910.60 for the first nine months of 2024, up from ¥84,501,559.50 in the same period of 2023[28] - Total comprehensive income reached ¥144,468,924.29, compared to ¥84,020,628.10 in the previous period, indicating a significant increase[30] Cash Flow - The net cash flow from operating activities increased by 72.50% to CNY 86,253,015.84, compared to CNY 50,002,395.72 in the previous year[4] - Cash inflow from operating activities totaled ¥623,141,060.45, up from ¥502,131,465.13, reflecting a growth of approximately 24%[30] - Net cash flow from operating activities was ¥86,253,015.84, compared to ¥50,002,395.72, representing a year-over-year increase of 72%[30] - Cash and cash equivalents at the end of the period stood at ¥301,072,011.45, down from ¥187,058,200.76, indicating a decrease in liquidity[31] - The company paid out ¥28,736,088.01 in dividends, an increase from ¥23,395,043.76, reflecting a commitment to returning value to shareholders[31] Assets and Liabilities - Total assets increased by 14.03% to CNY 1,316,081,970.99 as of September 30, 2024, compared to CNY 1,154,156,478.60 at the end of 2023[4] - The company’s total liabilities to assets ratio increased to 20.66% from 17.83% year-on-year, indicating a slight increase in leverage[4] - Current liabilities rose to ¥244,623,477.72 from ¥181,305,845.18, reflecting an increase of approximately 35%[22] - The company’s long-term investments decreased to ¥18,580,079.51 from ¥21,803,455.48, a decline of approximately 14.3%[23] Investments - The company’s investment activities resulted in a cash outflow of CNY 198,114,315.39, a 119.50% increase compared to the previous year, primarily due to increased purchases of financial products[6] - The company reported a significant increase in trading financial assets to CNY 190,396,465.74 as of September 30, 2024, compared to CNY 76,399,649.58 at the end of 2023, marking a growth of approximately 149.5%[19] - The company reported a total cash outflow from investment activities of ¥1,151,786,431.75, compared to ¥823,635,259.48, indicating increased investment expenditures[34] Shareholder Information - The total number of unrestricted shares increased from 68,294,887 to 69,171,487, representing a growth of 1.29%[8] - The proportion of unrestricted shares rose from 87.28% to 88.40% during the reporting period[8] - The top ten shareholders collectively hold 44,101,877 shares, accounting for 56.36% of total shares[9] - The company has no pledged or judicially frozen shares among its major shareholders[10] - The company has implemented a share buyback plan, which has been disclosed in a timely manner[12] Expenses - Total operating costs increased to ¥524,560,221.68, up 19.4% from ¥439,530,508.25 year-over-year[27] - Research and development expenses rose to ¥97,810,466.84, a 19.3% increase from ¥82,001,063.31 year-over-year[27] - The company reported a significant increase in sales expenses, which totaled ¥281,352,036.55, compared to ¥220,451,994.49 in the previous year, marking a 27.6% rise[27] - Tax expenses for the first nine months of 2024 were ¥21,620,293.55, compared to ¥15,206,747.24 in the same period of 2023, reflecting a 42.5% increase[28] Other Information - There were no significant legal disputes or external guarantees during the reporting period[12] - The company has established a unified voting agreement among five major natural person shareholders, collectively holding 30.83% of the shares[9] - The company conducted two rounds of entrusted wealth management using idle funds, totaling CNY 621,320,000.00, to enhance capital efficiency[15]
德源药业(832735) - 2024 Q3 - 季度财报